Advertisment
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Summary
- Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker
- Scemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs
- 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trial
- Kisqali NATALEE and MONALEESA data add to evidence of long-term benefits for early and metastatic breast cancer patients
Novartis will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2025 San Antonio Breast Cancer Symposium® (SABCS). Featured among these latest advances in hematology and oncology are 11 oral presentations, with the Phase III VAYHIT2 trial for ianalumab in immune thrombocytopenia (ITP) accepted as a late-breaker abstract.
“For decades, Novartis has redefined the future of hematology and oncology, and we’re building on that foundation with compelling new data presented at ASH and SABCS,” said Mark Rutstein, M.D., Global Head, Oncology Development, Novartis. “These data underscore how we seek to set new standards for transformative care, with the aim of turning cutting-edge innovation into meaningful impact for patients.”
View key highlights of data accepted by ASH HERE.
